Yahoo
NasdaqGS - Delayed Quote USD

PetMed Express, Inc. (PETS)

1.2000 +0.0100 (+0.84%)
At close: 4:00:00 PM EST
Chart Range Bar
Loading chart for PETS
  • Previous Close 1.1900
  • Open 1.1900
  • Bid 1.2000 x 100
  • Ask 1.2900 x 100
  • Day's Range 1.1500 - 1.2100
  • 52 Week Range 1.1500 - 4.1000
  • Volume 34,371
  • Avg. Volume 110,134
  • Market Cap (intraday) 26.015M
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3800
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 1.40
  • Zacks Rating Bearish

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

www.1800petmeds.com

189

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PETS
62.50%
S&P 500 (^GSPC)
10.17%

1-Year Return

PETS
53.31%
S&P 500 (^GSPC)
10.25%

3-Year Return

PETS
83.31%
S&P 500 (^GSPC)
74.66%

5-Year Return

PETS
95.41%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 44.36M
Earnings --
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q1

FY26

Q2

FY26

-20M
0
20M
40M
-60.0%
-40.0%
-20.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

1.40
1.40 Average
1.2000 Current
1.40 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/25/2026
Analyst Morgan Stanley
Rating Action Maintains
Rating Underweight
Price Action Lowers
Price Target 2.15 -> 1.4

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.34%

  • Return on Assets (ttm)

    -20.05%

  • Return on Equity (ttm)

    -78.56%

  • Revenue (ttm)

    168.86M

  • Net Income Avi to Common (ttm)

    -29.28M

  • Diluted EPS (ttm)

    -1.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.08M

  • Total Debt/Equity (mrq)

    1.80%

  • Levered Free Cash Flow (ttm)

    -15.95M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: